Two Transgenic Mouse Facilities are available to OSUCCC members. OSUCCC intends to supplement existing facilities at the OSU Biotechnology Center (OSUBC) and the Children's Hospital Research Foundation (CHRF) to increase their capacity to meet the requirements of Cancer Center members for transgenic animals. This avoids the substantial additional costs and the duplication of effort of establishing a third transgenic animal facility. The state-of-the-art OSUBC facility produces transgenic mice by pronuclear injection. It also creates embryonic stem (ES) cell lines and chimeric animals derived from these lines. The current size of the facility is sufficient to house approximately 2,000 mice. It is anticipated that by late summer of 1995, the facility will have completed an expansion into neighboring Pressey Hall which will increase the capacity of the Facility to 10,000 mice. The CHRF Transgenic Facility is located on the lower level of the Wexner Institute for Pediatric Research. This facility has two dedicated animal rooms and one procedure room with a total capacity of approximately 2,000 animals. The facility is equipped with state-of-the-art environmental controls, surgical instruments, and monitoring equipment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-22
Application #
5206778
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
22
Fiscal Year
1996
Total Cost
Indirect Cost
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E et al. (2018) Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res 4:26-38

Showing the most recent 10 out of 2602 publications